HLS Therapeutics Reports Q1 Revenue Growth and Highlights Momentum for New Cholesterol Drug
HLS Therapeutics reported first-quarter revenue of $12.9 million, a 2% year-over-year increase, while reaffirming its full-year guidance for revenue between $56 million to $60 million in 2026 and adjusted EBITDA of $18.5 million to $21 million. The company highlighted early success with the launch of NILEMDO, a cholesterol drug that generated nearly CAD 250,000 in sales within its first month.
Tickers: $MU
Topics: ebitda pharmaceuticals product_launch revenue_growth